We provide a comprehensive analysis of the potential of targeting C3/C3aR signaling as a novel GBM therapy, including the application of small-molecule antagonists, synergistic effects with radiotherapy, and the prospects for biomarker development based on liquid biopsy. The gene discussed is C3AR1; the disease is glioblastoma.